Immunohistochemical analysis of p53, APE1, hMSH2 and ERCC1 proteins in actinic cheilitis and lip squamous cell carcinoma

Histopathology

Volumn 58, Issue 3, 2011, Pages 352-360

  Souza, Ludmilla R ^a   Fonseca Silva, Thiago ^a   Pereira, Camila S ^a   Santos, Erivelton P ^a   Lima, Lucianne C ^b   Carvalho, Heloísa A ^b   Gomez, Ricardo S ^c   Guimarães, André L S ^a   De Paula, Alfredo M B ^a  

^a STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Actinic cheilitis; APE1; DNA repair proteins; ERCC1; HMSH2; Immunohistochemistry; Lip carcinogenesis; Lip squamous cell carcinoma; P53; Tumour suppressor protein

Indexed keywords

DNA REPAIR PROTEIN APE1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NUCLEAR PROTEIN; PROTEIN MSH2; PROTEIN P53; UNCLASSIFIED DRUG;

ACTINIC CHEILITIS; ADULT; AGED; ARTICLE; CHEILITIS; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIP CARCINOMA; LIP SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CHEILITIS; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIP NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79952090610     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03756.x     Document Type: Article

References (58)

1. De Visscher JG, van der Waal I. Etiology of cancer of the lip. A review. Int. J. Oral Maxillofac. Surg. 1998; 27; 199-203.
2. Luna-Ortiz K, Guemes-Meza A, Villavicencio-Valencia V, Mosqueda-Taylor A. Lip cancer experience in Mexico. An 11-year retrospective study. Oral Oncol. 2004; 40; 992-999.
3. Main JHP, Pavone MJ. Actinic cheilitis and carcinoma of the lip. J. Can. Dent. Assoc. 1994; 6; 113-116.
4. Nicolau SG, Baelus L. Chronic actinic cheilitis and cancer of the lower lip. Br. J. Dermatol. 1964; 76; 278-289.
5. Picascia DD, Robinson JK. Actinic cheilitis: a review of the etiology, differential diagnosis, and treatment. J. Am. Acad. Dermatol. 1987; 17; 255-264.
6. Jaber MA, Porter SR, Gilthorpe MS, Bedi R, Scully C. Risk factors for oral epithelial dysplasia, the role of smoking and alcohol. Oral Oncol. 1999; 35; 151-156.
7. Markopoulos A, Albanidou-Farmaki E, Kayavis I. Actinic cheilitis: clinical and pathologic characteristics in 65 cases. Oral Dis. 2004; 10; 212-216.
8. van Leeuwen MT, Grulich AE, McDonald SP et al. Immunosuppression and other risk factors for lip cancer after kidney transplantation. Cancer Epidemiol. Biomarkers Prev. 2009; 18; 561-569.
9. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000; 36; 256-263.
10. Jin S, Levine AJ. The p53 functional circuit. J. Cell Sci. 2001; 114; 4139-4140.
11. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351; 453-456.
12. Yamazakia Y, Hiraia ICA, Sugiuraa C et al. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 2003; 39; 163-169.
13. De Paula AM, Souza LR, Farias LC et al. Analysis of 724 cases of primary head and neck squamous cell carcinoma (HNSCC) with a focus on young patients and p53 immunolocalization. Oral Oncol. 2009; 45; 777-782.
14. Horta MC, de Assis LA, de Souza AF, de Araujo VC, Gomez RS, Aguiar MC. p53 and p21WAF1/CIP1 overexpression at the invasive front of lower lip squamous cell carcinoma. J. Oral Pathol. Med. 2007; 36; 88-92.
15. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat. Res. 2005; 577; 275-283.
16. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res. 2002; 511; 145-178.
17. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 2001; 8; 1076-1092.
18. Baross-Francis A, Andrew SE, Perfettini JL. Tumors of DNA mismatch repair-deficient hosts exhibit dramatic increases in genomic instability. Proc. Natl. Acad. Sci. U.S.A. 1998; 95; 8739-8743.
19. Cox EC, Degnen GE, Scheppe ML. Mutator gene studies in Escherichia coli: the mutS gene. Genetics 1972; 72; 551-567.
20. Hoffman PD, Wang H, Lawrence CW, Iwai S, Hanaoka F, Hays JB. Binding of MutS mismatch repair protein to DNA containing UV photoproducts, 'mismatched' opposite Watson-Crick and novel nucleotides, in different DNA sequence contexts. DNA Repair (Amst.) 2005; 4; 983-993.
21. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 2000; 20; 7980-7990.
22. Gillet LC, Scharer OD. Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev. 2006; 106; 253-276.
23. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. Oncogene 2002; 22; 8949-8965.
24. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman S, Wu X. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin. Cancer Res. 2007; 13; 3753-3758.
25. Gasior SL, Roy-Engel AM, Deininger PL. ERCC1/XPF limits L1 retrotransposition. DNA Repair (Amst.) 2008; 7; 983-989.
26. Niedernhofer LJ, Odijk H, Budzowsha M, van Drunen E, Maass A, Theil AF. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand crosslink-induced double-strand breaks. Mol. Cell. Biol. 2004; 24; 5776-5787.
27. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell. Mol. Life Sci. 2009; 66; 981-993.
28. Wallace SS. AP endonucleases and DNA glycosylases that recognize oxidative DNA damage. Environ. Mol. Mutagen. 1988; 12; 431-477.
29. Fishel ML, Kelley MR. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 2007; 28; 375-395.
30. Ando K, Hirao S, Kabe Y et al. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res. 2008; 36; 4327-4336.
31. Sobin L, Wittekind C eds. International Union Against Cancer (UICC): TNM classification of malignant tumours, 6th edn. New York: Wiley, 2002.
32. Barnes L, Eveson JW, Reichart P, Sindransky D. World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005.
33. Kujan O, Oliver RJ, Khattab A, Roberts SA, Thakker N, Sloan P. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006; 42; 987-993.
34. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J. Pathol. 1992; 166; 375-381.
35. Handra-Luca A, Couvelard A, Degott C, Flejou JF. Correlation between patterns of DNA mismatch repair hmlh1 and hmsh2 protein expression and progression of dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch. 2004; 444; 235-238.
36. De Paula AM, Gomez RS. Immunolocalization of p53, glutathione S-transferase pi and CD57 antigens in oral leukoplakia. Anticancer Res. 2001; 21; 379-385.
37. Sarasin A. The molecular pathways of ultraviolet-induced carcinogenesis. Mutat. Res. 1999; 428; 5-10.
38. Pfeifer GP, You YH, Besaratinia A. Mutations induced by ultraviolet light. Mutat. Res. 2005; 571; 19-31.
39. Burnworth B, Arendta S, Mufflera S et al. The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur. J. Cell Biol. 2007; 86; 1763-1780.
40. Fabbrocini G, Russo N, Pagliuca MC et al. p53, cyclin-D1, PCNA, AgNOR expression in squamous cell cancer of the lip: a multicenter study. Photodermatol. Photoimmunol. Photomed. 2000; 16; 172-177.
41. Raybaud-Diogene H, Tetu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur. J. Cancer B Oral Oncol. 1996; 32B; 143-149.
42. Izumi T, Hazra TK, Boldogh I et al. Requirement for human AP endonuclease 1 for repair of 3'-blocking damage at DNA single-strand breaks induced by reactive oxygen species. Carcinogenesis 2000; 21; 1329-1334.
43. Xu Y, Moore DH, Broshears J, Liu L, Wilson TM, Kelley MR. The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer. Anticancer Res. 1997; 17; 3713-3719.
44. Kelley MR, Cheng L, Foster R et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin. Cancer Res. 2001; 7; 824-830.
45. Ouellet V, Le PC, Guyot MC et al. SET complex in serous epithelial ovarian cancer. Int. J. Cancer 2006; 119; 2119-2126.
46. Wang X, Zhang J, Fan M et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009; 107; 547-554.
47. Koukourakis MI, Giatromanolaki A, Kakolyris S et al. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int. J. Radiat. Oncol. Biol. Phys. 2001; 50; 27-36.
48. Friedberg EC. How nucleotide excision repair protects against cancer. Nat. Rev. 2001; 1; 22-33.
49. de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis 2000; 21; 453-460.
50. Cheng L, Guan Y, Li L et al. Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol. Biomarkers Prev. 1999; 8; 801-807.
51. Parsons R, Li GM, Longley MJ et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75; 1227-1236.
52. Vogel U, Sorensen M, Hansen RD et al. Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett. 2007; 247; 159-165.
53. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 2003; 21; 1174-1179.
54. El-Naggar AK, Hurr K, Huff V, Clayman GL, Luna MA, Batsakis JG. Microsatellite instability in preinvasive and invasive head and neck squamous carcinoma. Am. J. Pathol. 1996; 148; 2067-2072.
55. Nunn J, Nagini S, Risk JM et al. Allelic imbalance at the DNA mismatch repair loci, hMSH2, hMLH1, hPMS1, hPMS2 and hMSH3, in squamous cell carcinoma of the head and neck. Oral Oncol. 2003; 39; 115-129.
56. Shia J, Ellis NA, Klimstra DS. The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch. 2004; 445; 431-441.
57. Ciavattini A, Piccioni M, Tranquilli AL, Filosa A, Pieramici T, Goteri G. Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol. Res. Pract. 2005; 201; 21-25.
58. Seifert M, Reichrath J. The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J. Mol. Histol. 2006; 37; 301-307.